← back to search

Richard M. Turner

Age UK · GB
Area of research
Pharmacology · Surgery
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Lipoproteins and Cardiovascular Health, Antiplatelet Therapy and Cardiovascular Diseases, and COVID-19 Clinical Research Studies.
h-index
34
citations
4,129
works
112
NIH funding
primary concept
Medicine
email

Recent publications

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
2025cited by 8position: contributordoi
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice
Journal of Clinical Oncology 2024cited by 16position: middledoi
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
The Lancet 2023cited by 498position: middledoi
The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin‐Associated Musculoskeletal Symptoms
Clinical Pharmacology & Therapeutics 2022cited by 324position: middledoi
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.
2022cited by 33position: contributordoi
Pharmacogenomics: Relevance and opportunities for clinical pharmacology.
2022cited by 15position: contributordoi
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.
2022cited by 10position: contributordoi
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
European Heart Journal - Cardiovascular Pharmacotherapy 2021cited by 49position: middledoi
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response.
2021cited by 21position: contributordoi
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Genes 2020cited by 302position: lastdoi
Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention.
2020cited by 12position: contributordoi
Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma <i>in situ</i>
British journal of surgery 2015cited by 101position: middledoi
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
British Journal of Clinical Pharmacology 2013cited by 128position: firstdoi

Grants

Nanoporous polymer particles and gels containing functionalized semi-rigid copolymer structures
NSF1609379$181,9432016–2018PIRePORTER
Sterically Congested and Stiffened Alternating Copolymers:  Synthesis, Solution and Solid-State Properties
NSF1206409$390,0152012–2016PIRePORTER
Precisely Functionalized Alternating Copolymers Based on Substituted Stilbene Monomers
NSF0905231$372,0002009–2012PIRePORTER
Improvement of Instruction in Marine Ecology
NSF7814013$9,5001978–1981PIRePORTER

Frequent collaborators

Munir Pirmohamed · Royal Liverpool and Broadgreen University Hospital NHS Trust5 papers (2020–2022) · 4 papers (2021–2022)Munir Pirmohamed · University of Liverpool2 papers (2020–2021)Anne Grete Semb · Institute for Rheumatic Diseases (Japan)2 papers (2021–2022)Sven Waßmann · Biomax Informatics (Germany)1 papers (2021–2021) · 1 papers (2013–2013)Li Gong · Tianjin University of Commerce1 papers (2022–2022) · 1 papers (2022–2022)Antonio Pinna · New York University1 papers (2015–2015) · 1 papers (2021–2021) · 1 papers (2022–2022)Patrick Sulzgruber · Medical University of Vienna1 papers (2022–2022)Basil S Lewis · Synta Pharmaceuticals (United States)1 papers (2022–2022)Gianluigi Savarese · American Institute of Biological Sciences1 papers (2022–2022)Daniel F. Carr · Institute for Integrative Systems Biology1 papers (2021–2021)Juan Carlos Kaski · Royal Brompton Hospital1 papers (2022–2022)Heinz Drexel · 1 papers (2022–2022)Christopher N Floyd · The King's College1 papers (2022–2022)Innocent G. Asiimwe · International Severe Acute Respiratory and Emerging Infection Consortium1 papers (2022–2022)Pascal Borry · Department of Public Health1 papers (2022–2022)